Rhabdomyosarcoma medical therapy

Rhabdomyosarcoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Rhabdomyosarcoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Rhabdomyosarcoma medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Rhabdomyosarcoma medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Rhabdomyosarcoma medical therapy
CDC on Rhabdomyosarcoma medical therapy
Rhabdomyosarcoma medical therapy in the news
Blogs on Rhabdomyosarcoma medical therapy
Directions to Hospitals Treating Rhabdomyosarcoma
Risk calculators and risk factors for Rhabdomyosarcoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

All patients with rhabdomyosarcoma require multimodality therapy with systemic chemotherapy, in conjunction with either surgery, radiation therapy (RT), or both modalities to maximize local tumor control.

Chemotherapy

Common agents include vincristine, cyclophosphamide, dactinomycin, adriamycin, ifosfamide, VP-16.